Lilly stops trial of muscle-sparing obesity drug because it's bad business. Others do the same.

[Meritocrat]

The monopolizing, future big Pharma trillionaire tyrant, Lilly just pulled the plug on a trial running bimagrumab. The trial was originally set to end in late 2026 and it was started by small firm, Versanis bio, a startup. Lilly bought versanis two years ago and now ended the trial. Bimagrumab had already shown incredible results with reducing muscle loss to under 10% during long-term fat loss. When it was used alongside a GLP-1 drug, not only did weight loss increase, but so did lean mass.

"The study stoppage comes as the FDA appears to be indicating that drugs like bimagrumab may need to do more than just improve muscle composition.."

Crony capitalism aka plutocracy aka oligarchy at work. Clearly, the plebes aren't meant to enjoy the fruits designed for the Patricians.

Another firm halted testing of their myostatin inhibtor with GLP's. "Veru earlier this week said the agency “now guides that incremental weight loss” over a GLP-1 drug alone “is an acceptable primary endpoint to support approval.” Veru’s shares fell 3% on Tuesday following that announcement, and another 3% Thursday."

It's an actual trend with many other pharmaceutical firms doing the same thing.

https://www.biopharmadive.com/news/lilly-terminate-obesity-trial-bimagrumab-muscle-diabetes/761105/

 

[Blueeyedme]

Interesting piece. It’s notable that neither Novo Nordisk or Eli Lilly could figure out how to make money with bimagrumab along with the FDA signaling they may now even approve it. In the end, it’s a business decision.

 

[reta-stacker]

Thanks for posting this interesting piece. I read the articel as well. I don't understand one thing: the FDA statement that “that incremental weight loss” over a GLP-1 drug alone “is an acceptable primary endpoint to support approval.” Doesn't that signal that the FDA will consider approval of muscle mass preservation drugs as a supplement to offset the GLP impact on muscle mass? And therefore isn't that encouragement to continue with the trials? If the pharma companies went this far with their trials, wouldn;t this FDA signal encourage completion of the trials? I must be missing something.

 

[UpDownLeftRightAS*]

This article is over a year old. Lilly may have decided to call it a wash on their 1.8B purchase of Versainis but Veru has shown great results and is now in Phase II trials